Poonam Gupta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Poonam Gupta has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Amandeep Kaur
Chitkara University Institute of Engineering and Technology Chitkara University, Rajpura, India
1 shared publication - Aqib Sarfraz
Technology Dissemination and Computational Biology Division CSIR‐Central Institute of Medicinal and Aromatic Plants Lucknow Uttar Pradesh India
1 shared publication - Feroz Khan
Technology Dissemination and Computational Biology Division CSIR‐Central Institute of Medicinal and Aromatic Plants Lucknow Uttar Pradesh India
1 shared publication Jyoti Yadav
Technology Dissemination and Computational Biology Division CSIR-Central Institute of Medicinal and Aromatic Plants P.O. – CIMAP Kukrail Picnic Spot Road 226015 Lucknow (U.P.) India
1 shared publication- Palak Singh
Technology Dissemination and Computational Biology Division CSIR-Central Institute of Medicinal and Aromatic Plants P.O. – CIMAP Kukrail Picnic Spot Road 226015 Lucknow (U.P.) India
1 shared publication - Rahul Kumar Garg
Asian College of Pharmacy, Udaipur, India
1 shared publication
Latest Publications
- 29 July 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (29)
Evaluation of Phytochemicals for Anti‐Tubercular Potential Targeting Enoyl‐Acyl Carrier Protein Reductase (InhA): An In Silico Approach
Tuberculosis (TB) caused by the Mycobacterium tuberculosis (MTB) pathogen is a serious contagious illness that endangers the public's health. However, TB is treatable but due to the result of ineffective and protracted medication, MDR‐MTB and XDR‐MTB were able to develop, making their eradication highly challenging and necessitating potential treatments to be cured. This study aimed to identify the novel inhibitor for the InhA enzyme, a potential target of MTB . Initially, 2721 phytochemicals libraries were screened for ADME/Tox profiling and 49 phytochemicals were filtered out. Moreover, these phytochemicals with reference inhibitor triclosan were docked against InhA (PDB ID: 1BVR)., were showing binding energies ranging from −9.16–−6.3 kcal/mol, whereas triclosan showed −6.90 kcal/mol of binding energy. The docking results reveal that irilone (−9.16 kcal/mol) and aurantio‐obtusin (−8.84 kcal/mol) exhibit promising binding energy and perfectly occupy the binding site of InhA. Furthermore, molecular dynamics simulation (MDS) and MMGBSA studies showed better affinities of selected compounds in terms of stability, compactness, flexibility, and total BFE in complexes with InhA. This study concluded that irilone and aurantio‐obtusin could be promising InhA inhibitors based on their impressive pharmacokinetic profiling, toxicity, binding affinity, and stability. However experimental validation is a subject of further research.
- 29 July 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (29)
Evaluation of Phytochemicals for Anti‐Tubercular Potential Targeting Enoyl‐Acyl Carrier Protein Reductase (InhA): An In Silico Approach
Tuberculosis (TB) caused by the Mycobacterium tuberculosis (MTB) pathogen is a serious contagious illness that endangers the public's health. However, TB is treatable but due to the result of ineffective and protracted medication, MDR‐MTB and XDR‐MTB were able to develop, making their eradication highly challenging and necessitating potential treatments to be cured. This study aimed to identify the novel inhibitor for the InhA enzyme, a potential target of MTB . Initially, 2721 phytochemicals libraries were screened for ADME/Tox profiling and 49 phytochemicals were filtered out. Moreover, these phytochemicals with reference inhibitor triclosan were docked against InhA (PDB ID: 1BVR)., were showing binding energies ranging from −9.16–−6.3 kcal/mol, whereas triclosan showed −6.90 kcal/mol of binding energy. The docking results reveal that irilone (−9.16 kcal/mol) and aurantio‐obtusin (−8.84 kcal/mol) exhibit promising binding energy and perfectly occupy the binding site of InhA. Furthermore, molecular dynamics simulation (MDS) and MMGBSA studies showed better affinities of selected compounds in terms of stability, compactness, flexibility, and total BFE in complexes with InhA. This study concluded that irilone and aurantio‐obtusin could be promising InhA inhibitors based on their impressive pharmacokinetic profiling, toxicity, binding affinity, and stability. However experimental validation is a subject of further research.
- 4 August 2021
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1426-1433
Challenges facing AI and Big data for Resource-poor Healthcare System
During the last decade, major advancements in the health-care system have developed by offering numerous benefits to the patients throughout the world but resource-poor countries are not benefited through the best practices of health-care due to the lack of educated health-care providers, infrastructure, financial and technical issues, etc. Health-care systems in resource-poor countries face many challenges including increased healthcare cost, patient safety, overtreatment and failure to adopt best practices for health-care. In such countries, massive data generate from various resources including medical imaging, patient record, pharmaceutical reports, and medical devices. The exponential growth in medical data and advancement in health-care technologies focus data analysts to come up with innovative solutions for improving health-care practices in poor countries. Big data analytics provide tools to collect manage and analyze structured and unstructured medical data to find useful insights. Complexity and volume of medical data also show that, Artificial intelligence (AI) has the ability to approximate conclusions without direct human input, which can be applied in the health-care system of resource-poor countries and is now being utilized to further develop health services in high-income countries. Numerous investigations show that, AI performs better than humans in certain health-care undertakings such as diagnosis of cancer, tumor, heart diseases, radiology, etc. Popular AI techniques include machine learning methods such as neural network, support vector machine, and deep learning for structured data as well as natural language processing for unstructured data. There is a variety of hurdles around the use of big data and AI in health-care includes regulation, permission, transparency, and accountability. Also, the collection of data from an individual-a prerequisite for big data analytics is a technical and ethical issue. There are a lot of challenges for AI and big data in health-care but efforts need to be made before these techniques can be deployed in ethical and safe way. In this chapter, we discuss the challenges that AI and big data techniques face in resource-poor health care system and how it can be used to improve health outcomes in resource-poor countries.
- 4 August 2021
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1426-1433
Challenges facing AI and Big data for Resource-poor Healthcare System
During the last decade, major advancements in the health-care system have developed by offering numerous benefits to the patients throughout the world but resource-poor countries are not benefited through the best practices of health-care due to the lack of educated health-care providers, infrastructure, financial and technical issues, etc. Health-care systems in resource-poor countries face many challenges including increased healthcare cost, patient safety, overtreatment and failure to adopt best practices for health-care. In such countries, massive data generate from various resources including medical imaging, patient record, pharmaceutical reports, and medical devices. The exponential growth in medical data and advancement in health-care technologies focus data analysts to come up with innovative solutions for improving health-care practices in poor countries. Big data analytics provide tools to collect manage and analyze structured and unstructured medical data to find useful insights. Complexity and volume of medical data also show that, Artificial intelligence (AI) has the ability to approximate conclusions without direct human input, which can be applied in the health-care system of resource-poor countries and is now being utilized to further develop health services in high-income countries. Numerous investigations show that, AI performs better than humans in certain health-care undertakings such as diagnosis of cancer, tumor, heart diseases, radiology, etc. Popular AI techniques include machine learning methods such as neural network, support vector machine, and deep learning for structured data as well as natural language processing for unstructured data. There is a variety of hurdles around the use of big data and AI in health-care includes regulation, permission, transparency, and accountability. Also, the collection of data from an individual-a prerequisite for big data analytics is a technical and ethical issue. There are a lot of challenges for AI and big data in health-care but efforts need to be made before these techniques can be deployed in ethical and safe way. In this chapter, we discuss the challenges that AI and big data techniques face in resource-poor health care system and how it can be used to improve health outcomes in resource-poor countries.